Tetrahydrobiopterin as a Treatment for Autism Spectrum Disorders: A Double-Blind, Placebo-Controlled Trial

2013 ◽  
Vol 23 (5) ◽  
pp. 320-328 ◽  
Author(s):  
Cheryl Klaiman ◽  
Lynne Huffman ◽  
Lauren Masaki ◽  
Glen R. Elliott
Keyword(s):  
Autism Spectrum Disorders ◽  
Controlled Trial ◽  
Autism Spectrum ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Spectrum Disorders

scholarly journals Assessment the Efficacy of Atomoxetine in Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial

2018 ◽  
Vol 12 (2) ◽  
Author(s):  
Mahbobeh Eslamzadeh ◽  
Paria Hebrani ◽  
Fatemeh Behdani ◽  
Malihee Dadgar Moghadam ◽  
Leili Panaghi ◽  
...  
Keyword(s):  
Autism Spectrum Disorders ◽  
Controlled Trial ◽  
Autism Spectrum ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Spectrum Disorders

scholarly journals A Double-Blind Placebo-Controlled Trial of levetiracetam for Global Severity in Child Autism Spectrum Disorders

2018 ◽  
Vol 3 (10) ◽  
Author(s):  
N. A. Aliyev ◽  
Z. N. Aliyev
Keyword(s):  
Autism Spectrum Disorders ◽  
Placebo Group ◽  
Side Effects ◽  
Rating Scale ◽  
Autism Spectrum ◽  
Repetitive Behaviors ◽  
Double Blind ◽  
Global Improvement ◽  
Double Blind Placebo ◽  
Spectrum Disorders

Objectives: The effects of levetiracetam and placebo on global severity were compared in Child Autism Spectrum Disorders (ASD). Materials and methods: Childs with ASDs were enrolled in a 12-week double-blind placebo-controlled levetiracetamtrial. Fifty were randomly assigned to levetiracetam (n=50) or placebo (n=50).The mean maximum dosage for levetiracetamwas 950.50±279.19 mg/day Repetitive behaviors were measured with the Clinical Global Impression (CGI) improvement scale. Results: There was a significant treatment-by-time interaction indicating a significantly greater reduction in repetitive behaviors across time for levetiracetamthan for placebo. With overall response defined as a CGI global improvement score of 2 or less, there were significantly more responders at week 12 in the levetiracetamgroup than in the placebo group. The risk ratio was 1.5 for CGI global improvement (responders: levetiracetam, 50%; placebo, 10%). Side effects were not observed. Conclusions: levetiracetamtreatment, compared to placebo, resulted in significantly greater improvement in global severity behaviors, according to CGI rating scale. levetiracetamappeared to be well tolerated movement score of 2 or less, there were significantly more responders at week 12 in the levetiracetamgroup than in the placebo group. Side effects were not observed.

scholarly journals Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial

2012 ◽  
Vol 3 (1) ◽  
pp. 16 ◽  
Author(s):  
Evdokia Anagnostou ◽  
Latha Soorya ◽  
William Chaplin ◽  
Jennifer Bartz ◽  
Danielle Halpern ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Autism Spectrum Disorders ◽  
Controlled Trial ◽  
Autism Spectrum ◽  
Adults With Autism ◽  
Randomized Controlled ◽  
Spectrum Disorders
Sign in / Sign up

Export Citation Format

Share Document